Climb Bio Spotlights Budoprutug in CD19 Targeting Webcast
Event summary
- Climb Bio to host R&D Spotlight webcast on May 5, 2026, focusing on budoprutug, its anti-CD19 monoclonal antibody.
- Budoprutug is in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE).
- Subcutaneous formulation of budoprutug completed dosing in healthy volunteers.
- David Jayne, MD, Professor at University of Cambridge, to join management team during the event.
The big picture
Climb Bio's focus on budoprutug underscores the growing interest in CD19-targeting therapies for immune-mediated diseases. The webcast highlights the company's strategic push to position budoprutug as a key player in treating pMN, ITP, and SLE, areas with significant unmet medical needs. The inclusion of a prominent academic expert suggests a bid to bolster credibility amid competitive pressures.
What we're watching
- Clinical Progress
- How budoprutug's clinical trial results in pMN, ITP, and SLE will shape its commercial potential.
- Formulation Strategy
- The pace at which the subcutaneous formulation of budoprutug advances towards patient access.
- Competitive Positioning
- Whether Climb Bio can differentiate budoprutug in the crowded CD19 targeting space.
Related topics